Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer

被引：14

作者：

Tone, Mari ^{[1
]}

Izumo, Takehiro ^{[1
]}

Awano, Nobuyasu ^{[1
]}

Kuse, Naoyuki ^{[1
]}

Inomata, Minoru ^{[1
]}

Jo, Tatsunori ^{[1
]}

Yoshimura, Hanako ^{[1
]}

Miyamoto, Shingo ^{[2
]}

Kunitoh, Hideo ^{[2
]}

机构：

[1] Japanese Red Cross Med Ctr, Dept Resp Med, Shibuya Ku, Tokyo, Japan

[2] Japanese Red Cross Med Ctr, Dept Med Oncol, Shibuya Ku, Tokyo, Japan

来源：

LUNG CANCER MANAGEMENT | 2019年 / 8卷 / 02期

关键词：

immune checkpoint inhibitor; NSCLC; salvage chemotherapy; RANDOMIZED PHASE-III; RESPONSE RATES; DOCETAXEL; NIVOLUMAB; PEMBROLIZUMAB; VINORELBINE; CARBOPLATIN; TRIAL; CELLS;

D O I：

10.2217/lmt-2019-0001

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. Patients & methods: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. Results: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. Conclusion: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.

引用

页数：7

共 50 条

[31] Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy
Weis, Taylor M.
Hough, Shannon
Reddy, Haritha G.
Daignault-Newton, Stephanie
Kalemkerian, Gregory P.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (03) : 564 - 571
[32] A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
Pacheco, Jose M.
Camidge, D. Ross
Doebele, Robert C.
Schenk, Erin
FRONTIERS IN ONCOLOGY, 2019, 9
[33] Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
Lim, Sung Won
Ahn, Myung-Ju
KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (01) : 50 - 59
[34] Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases
Wei, Yuxi
Xu, Yan
Wang, Mengzhao
CHINESE MEDICAL JOURNAL, 2023, 136 (13) : 1523 - 1531
[35] Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors
Ichiki, Yoshinobu
Fukuyama, Takashi
Ueno, Mari
Kanasaki, Yoshiro
Goto, Hidenori
Takahashi, Mai
Mikami, Shuji
Kobayashi, Noritada
Nakanishi, Kozo
Hayashi, Shinichi
Ishida, Tsuyoshi
TRANSLATIONAL LUNG CANCER RESEARCH, 2022, : 2192 - 2207
[36] Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma
Kourie, Hampig Raphael
Kanaan, Hassan
Awada, Gil
Awada, Ahmad Hussein
FUTURE ONCOLOGY, 2017, 13 (12) : 1097 - 1103
[37] Safety of current immune checkpoint inhibitors in non-small cell lung cancer
Abdayem, Pamela
Planchard, David
EXPERT OPINION ON DRUG SAFETY, 2021, 20 (06) : 651 - 667
[38] Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status
Kano, Hirohisa
Ichihara, Eiki
Harada, Daijiro
Inoue, Koji
Kayatani, Hiroe
Hosokawa, Shinobu
Kishino, Daizo
Watanabe, Kazuhiko
Ochi, Nobuaki
Oda, Naohiro
Hara, Naofumi
Ninomiya, Kiichiro
Hotta, Katsuyuki
Maeda, Yoshinobu
Kiura, Katsuyuki
CANCER SCIENCE, 2020, 111 (10) : 3739 - 3746
[39] Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?
Cheng, Monica
Durm, Greg
Hanna, Nasser
Einhorn, Lawrence H.
Kong, Feng-Ming
FUTURE ONCOLOGY, 2017, 13 (28) : 2503 - 2505
[40] Immune checkpoint inhibitors in non-small cell lung cancer
Eberhardt, Wilfried Ernst Erich
ONKOLOGE, 2017, 23 (10): : 838 - 844

← 1 2 3 4 5 →